DICE Therapeutics, Inc.

DICEDelisted Aug 9, 2023

Industry: Pharmaceutical Preparations
SEC CIK: 0001645569

SEC filings (opens in a new tab)

DICE Therapeutics, Inc. was delisted on Aug 9, 2023; its insiders filed their last Form 4 on Aug 9, 2023; 160 institutions reported holding it in 13F filings for Q2 2023, worth $2.12B in total; Fairfax Financial was the only superinvestor holding it.

Key figures

Market cap: –; Not available
Insider buys: 0; Open market, last 90 days
Insider sells: 0; Open market, last 90 days
13F holders: 160; Q2 2023, +45 vs. previous quarter
13F value: $2.12B; Reported value at the end of Q2 2023
Superinvestors holding: 1; At the end of Q2 2023

Financials

See financial statements

From SEC filings, in USD.

Revenue, FY2022: –; No comparable prior period
Net income, FY2022: -$83.9M; No comparable prior period
Free cash flow, FY2022: -$66.6M; No comparable prior period
Revenue, Q2 FY2023: –; No comparable prior period

Short interest

See short data

From FINRA, settlement date Oct 30, 2026.

Short interest: 3.66K; Shares sold short
Change: −3.71K; −50.4% vs. previous
Days to cover: 2.67; At average daily volume

Superinvestors holding DICE, Q2 2023

Go to the superinvestors tab

1 superinvestor reports holding DICE Therapeutics, Inc. on Form 13F. Percentages are the stock's share of each portfolio.

Fairfax Financial

Prem Watsa

0.3%

DICE Therapeutics, Inc.'s share of the portfolio

Shares: 130,000
Value: $6.04M

Latest insider trades

See all insider trades

Open-market purchases and sales by DICE Therapeutics, Inc. insiders from Form 4, newest first.

Insider trades
Filed (ET)	Trade date	Filing delay	Insider	Transaction	Shares	Avg price	Value	Holding change	Flags
Jun 23, 2023 (view filing)5:36 PM ET	Jun 22	1 day	Northpond Ventures GP, LLC and 4 others10% Owner	SSale	−2.49M	$46.50	−$115.9M	−93.7%166.3K after	2 lots
Jun 2, 2023 (view filing)	Jun 1	1 day	Jacobsen John R.CSO	SSale	−18.8K	$30.53	−$572.4K	−11.3%147.5K after	2 lots
May 9, 2023 (view filing)	May 5	4 days	Scheller Richard HDirector	SSale	−84.1K	$38.51	−$3.24M	−90.9%8.43K after
May 5, 2023 (view filing)	May 3	2 days	Robertson Scott M.CFO & CBO	SSale	−18.8K	$36.55	−$685.3K	−8.7%198.0K after
May 5, 2023 (view filing)	May 3	2 days	Timothy LuCMO	SSale	−10.0K	$36.54	−$365.4K	−6.2%152.3K after
May 5, 2023 (view filing)	May 3	2 days	Judice KevinCEO	SSale	−13.7K	$36.50	−$500.0K	−1.7%799.7K after
Apr 19, 2023 (view filing)	Apr 18	1 day	Jacobsen John R.CSO	SSale	−16.4K	$30.08	−$493.1K	−9.0%166.2K after
Apr 4, 2023 (view filing)	Mar 31	4 days	Jacobsen John R.CSO	SSale	−773	$30.00	−$23.2K	−0.4%182.6K after
Mar 30, 2023 (view filing)5:03 PM ET	Mar 28-30	2 days	RA Capital Healthcare Fund LP and 4 othersDirector, 10% Owner	PPurchase	+509.1K	$29.07	+$14.8M	+7.8%7.07M after	3 lots
Mar 30, 2023 (view filing)	Mar 28-29	2 days	Jacobsen John R.CSO	SSale	−1.59K	$30.03	−$47.9K	−0.9%183.4K after	2 lots

Top 10 13F holders, Q2 2023

See all 160 holders

The largest institutional positions in DICE Therapeutics, Inc. at the end of Q2 2023; share changes are against Q1 2023.

Institutions holding DICE in Q2 2023
Institution	Shares	Value	% of portfolio	Change in shares	Action
Ra Capital Management, L.P.	7,856,612	$365.0M	6.89%	00.0%	Unchanged
BlackRock Inc.	2,895,307	$134.5M	0.00%	−117,134−3.9%	Reduced
FMR LLC	2,239,223	$104.0M	0.01%	−3,441,317−60.6%	Reduced
Avoro Capital Advisors LLC	2,199,342	$102.2M	1.39%	−1,750,658−44.3%	Reduced
Alpine Associates Management Inc.	2,116,800	$98.3M	4.43%	+2,116,800	New
Driehaus Capital Management LLC	2,038,257	$94.7M	1.20%	+36,704+1.8%	Added
Vanguard Group Inc	1,957,417	$90.9M	0.00%	+29,161+1.5%	Added
Magnetar Financial LLC	1,155,887	$53.7M	1.18%	+1,155,887	New
Pentwater Capital Management LP	1,080,507	$50.2M	0.63%	+1,080,507	New
UBS Oconnor LLC	1,075,000	$49.9M	1.06%	+1,075,000	New